Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO
The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery.
- EligibilityCriteria: Inclusion Criteria:  Age ≥ 18 years old VA-ECMO or VV-ECMO was accepted after cardiac surgery. The ECMO treatment team believes that systemic anticoagulation is needed Sign the informed consent form  Exclusion Criteria:  The researchers believe that there are other causes of active bleeding that are not suitable to participate in this study. Long-term use of anticoagulants before establishment of ECMO Antiplatelet drugs were used before the establishment of ECMO Severe liver insufficiency Connective tissue disease There is a history of allergy to heparin or nemolastat mesylate. Pregnant Previous diagnosis of heparin-induced thrombocytopenia Expect to die within 48 hours ECPR - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult